TALOPH(SH:600222)2025-04-29 11:40Financial Performance - The company's operating revenue for Q1 2025 was ¥323,274,192.26, a decrease of 35.23% compared to ¥499,111,557.06 in the same period last year[3] - Net profit attributable to shareholders was ¥1,530,570.06, down 92.80% from ¥21,258,639.34 year-on-year[3] - The company reported a basic earnings per share of ¥0.0028, a decline of 92.65% from ¥0.0381 in the same period last year[3] - The company reported a net profit of CNY 2,631,142.99 for Q1 2025, down 87.3% from CNY 20,521,428.43 in Q1 2024[17] - The total comprehensive income attributable to the parent company owners was CNY -5,065,852.08, compared to CNY 12,579,812.36 in the previous period, indicating a significant drop[18] Cash Flow - The net cash flow from operating activities improved significantly to ¥10,950,449.57, compared to a negative cash flow of ¥115,823,793.88 in the previous year, marking a 109.45% change[3] - Cash received from sales of goods and services was CNY 414,804,628.03, down from CNY 479,171,900.81, reflecting a decrease of approximately 13.5%[22] - The net cash flow from investing activities was CNY 89,445,610.07, compared to CNY 100,273,498.41 in the previous period, showing a decline of about 10.8%[23] - Cash inflow from financing activities was CNY 424,609,780.95, an increase from CNY 266,303,164.84, representing a growth of approximately 59.4%[23] - The ending cash and cash equivalents balance was CNY 367,798,047.03, up from CNY 213,271,783.83, indicating an increase of about 72.5%[23] - The total operating cash outflow was CNY 406,284,927.59, compared to CNY 596,965,172.27 in the previous period, indicating a reduction of about 32%[22] Assets and Liabilities - The total assets at the end of the reporting period increased by 2.17% to ¥3,565,530,775.02 from ¥3,489,768,020.93 at the end of the previous year[4] - Cash and cash equivalents increased to CNY 403,944,947.01 as of March 31, 2025, compared to CNY 180,039,805.83 at the end of 2024[12] - The company’s total liabilities increased to CNY 1,934,505,598.17 from CNY 1,863,525,871.55 at the end of 2024[14] - The long-term investments increased to CNY 205,932,079.69 as of March 31, 2025, compared to CNY 197,722,648.31 at the end of 2024[12] - The company’s inventory stood at CNY 364,819,936.82, slightly down from CNY 367,673,786.87 at the end of 2024[12] Segment Performance - The gross margin in the traditional Chinese medicine segment improved slightly despite a decrease in revenue due to market conditions[9] - The company is focusing on high-value customers in the Chinese medicine decoction pieces segment, resulting in a revenue decline but an increase in gross margin[9] - The pharmaceutical research and development service segment faced increased market competition, leading to a decrease in revenue, although project gross margins improved through cost control measures[9] - Gross profit margin for the pharmaceutical formulation segment was 48.69%, a decrease of 2.41% year-over-year[10] - Revenue from traditional Chinese medicine pieces was CNY 180,761,496.70, with a year-over-year decline of 21.57%[10] Return on Investment - The weighted average return on net assets decreased to 0.10%, down from 1.34% in the previous year[3] - The basic and diluted earnings per share were CNY 0.0028, down from CNY 0.0381 in the previous period, reflecting a decrease of approximately 92.6%[18] Sales and Marketing - The company has integrated its existing sales channels, which has impacted product sales during the transition period[9]